MedTrace Logo

Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma

NCT00988312 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2009-10-02

No results posted yet for this study

Summary

Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.

Conditions

Interventions

BIOLOGICAL

autologous idiotype-protein pulsed dendritic cells

Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks

Sponsors & Collaborators

  • University Hospital Carl Gustav Carus

    lead OTHER

Principal Investigators

  • Susanne Gretzinger, MD · University Hospital Dresden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2004-02-29
Completion
2004-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00988312 on ClinicalTrials.gov